Interactions between cyclic nucleotide phosphodiesterase 11 catalytic site and substrates or tadalafil and role of a critical Gln-869 hydrogen bond

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 1, 2009, Pages 133-141

  Weeks II, James L ^a   Corbin, Jackie D ^a   Francis, Sharron H ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 11; GLUTAMINE; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; HYDROGEN BOND; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; CARBOLINES; CATALYTIC DOMAIN; CATTLE; CRYSTALLOGRAPHY, X-RAY; GLUTAMINE; HUMANS; HYDROGEN BONDING; MUTAGENESIS, SITE-DIRECTED; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SUBSTRATE SPECIFICITY;

EID: 70349327596     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.156935     Document Type: Article

References (40)

1. Andrews PR, Craik DJ, and Martin JL (1984) Functional group contributions to drug-receptor interactions. J Med Chem 27:1648-1657.
2. Beavo J, Houslay MD, and Francis SH (2006) Cyclic nucleotide phosphodiesterase superfamily, in Cyclic Nucleotide Phosphodiesterases in Health and Disease (Beavo J, Francis SH, and Houslay MD eds) pp 3-17, CRC Press, Boca Raton.
3. Beltman J, Becker DE, Butt E, Jensen GS, Rybalkin SD, Jastorff B, and Beavo JA (1995) Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: topology of the catalytic domains. Mol Pharmacol 47:330-339.
4. Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, and Corbin JD (2004) Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase- 5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66:144-152. (Pubitemid 38822097)
5. Blount MA, Zoraghi R, Ke H, Bessay EP, Corbin JD, and Francis SH (2006) A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase- 5 dimerization. Mol Pharmacol 70:1822-1831. (Pubitemid 44776442)
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Braumann T, Erneux C, Petridis G, Stohrer WD, and Jastorff B (1986) Hydrolysis of cyclic nucleotides by a purified cGMP-stimulated phosphodiesterase: structural requirements for hydrolysis. Biochim Biophys Acta 871:199-206. (Pubitemid 16085079)
8. Butt E, Beltman J, Becker DE, Jensen GS, Rybalkin SD, Jastorff B, and Beavo JA (1995) Characterization of cyclic nucleotide phosphodiesterases with cyclic AMP analogs: topology of the catalytic sites and comparison with other cyclic AMPbinding proteins. Mol Pharmacol 47:340-347.
9. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Christensen AE, Selheim F, de Rooij J, Dremier S, Schwede F, Dao KK, Martinez A, Maenhaut C, Bos JL, Genieser HG, et al. (2003) cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J Biol Chem 278:35394-35402. (Pubitemid 37102308)
11. Conti M and Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511.
12. Corbin JD and Døskeland SO (1983) Studies of two different intrachain cGMPbinding sites of cGMP-dependent protein kinase. J Biol Chem 258:11391-11397.
13. Couchie D, Petridis G, Jastorff B, and Erneux C (1983) Characterization of phosphodiesterase catalytic sites by means of cyclic nucleotide derivatives. Eur J Biochem 136:571-575.
14. Daugan A-M (2000), inventor; ICOS Corp., assignee. Use of cGMP-phosphodiesterase in methods and composition to treat impatience. U.S. Patent 6,140,329.
15. Døskeland SO and Ogreid D (1984) Characterization of the interchain and intrachain interactions between the binding sites of the free regulatory moiety of protein kinase I. J Biol Chem 259:2291-2301.
16. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, and Phillips SC (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci U S A 97:3702-3707. (Pubitemid 30183366)
17. Fink TL, Francis SH, Beasley A, Grimes KA, and Corbin JD (1999) Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J Biol Chem 274:34613-34620. (Pubitemid 129509498)
18. Francis SH, Sekhar KR, Rouse AB, Grimes KA, and Corbin JD (2003) Single step isolation of sildenafil from commercially available Viagra tablets. Int J Impot Res 15:369-372.
19. Francis SH, Thomas MK, and Corbin JD (1990) Cyclic GMP-binding cyclic GMPspecific phosphodiesterase from lung, in Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action (Beavo J and Houslay MD eds) p 358, John Wiley and Sons, New York.
20. Francis SH, Wolfe L, and Corbin JD (1991) Purification of type I alpha and type I beta isozymes and proteolyzed type I beta monomeric enzyme of cGMP-dependent protein kinase from bovine aorta. Methods Enzymol 200:332-341.
21. Hetman JM, Robas N, Baxendale R, Fidock M, Phillips SC, Soderling SH, and Beavo JA (2000) Cloning and characterization of two splice variants of human phosphodiesterase 11A. Proc Natl Acad Sci U S A 97:12891-12895. (Pubitemid 30840512)
22. Huai Q, Colicelli J, and Ke H (2003) The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry 42:13220-13226. (Pubitemid 37420675)
23. Huai Q, Liu Y, Francis SH, Corbin JD, and Ke H (2004) Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1- methylxanthine suggest a conformation determinant of inhibitor selectivity. J Biol Chem 279: 13095-13101. (Pubitemid 38445887)
24. Ke H and Wang H (2006) Structure, catalytic mechanism, and inhibitor selectivity of cyclic nucleotide phosphodiesterases, in Cyclic Nucleotide Phosphodiesterases in Health and Disease (Beavo J, Francis SH, and Houslay MD eds) pp 607-625, CRC Press, Boca Raton.
25. Richter W and Conti M (2004) The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases. J Biol Chem 279:30338-30348. (Pubitemid 38937961)
26. Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, Kim JH, Moon J, Yoon JM, Hyun YL, Kim E, et al. (2003) Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 425:98-102. (Pubitemid 37101725)
27. Thomas MK, Francis SH, Beebe SJ, Gettys TW, and Corbin JD (1992) Partial mapping of cyclic nucleotide sites and studies of regulatory mechanisms of phosphodiesterases using cyclic nucleotide analogues. Adv Second Messenger Phosphoprotein Res 25:45-53.
28. Wang H, Liu Y, Chen Y, Robinson H, and Ke H (2005) Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J Biol Chem 280:30949-30955. (Pubitemid 41291827)
29. Wang H, Liu Y, Hou J, Zheng M, Robinson H, and Ke H (2007) Structural insight into substrate specificity of phosphodiesterase 10. Proc Natl Acad Sci U S A 104:5782-5787. (Pubitemid 47175611)
30. Wang H, Liu Y, Huai Q, Cai J, Zoraghi R, Francis SH, Corbin JD, Robinson H, Xin Z, Lin G, et al. (2006) Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem 281:21469-21479. (Pubitemid 44115485)
31. Wang H, Yan Z, Yang S, Cai J, Robinson H, and Ke H (2008a) Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. Biochemistry 47:12760-12768.
32. Wang H, Ye M, Robinson H, Francis SH, and Ke H (2008b) Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol 73:104-110. (Pubitemid 350294201)
33. Weeks JL 2nd, Zoraghi R, Francis SH, and Corbin JD (2007) N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization. Biochemistry 46: 10353-10364.
34. Wilkinson AJ, Fersht AR, Blow DM, and Winter G (1983) Site-directed mutagenesis as a probe of enzyme structure and catalysis: tyrosyl-tRNA synthetase cysteine-35 to glycine-35 mutation. Biochemistry 22:3581-3586.
35. Xu RX, Rocque WJ, Lambert MH, Vanderwall DE, Luther MA, and Nolte RT (2004) Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram. J Mol Biol 337:355-365.
36. Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T, and Omori K (2000) Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J Biol Chem 275:31469-31479. (Pubitemid 30757819)
37. Zhang KY, Card GL, Suzuki Y, Artis DR, Fong D, Gillette S, Hsieh D, Neiman J, West BL, Zhang C, et al. (2004) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell 15:279-286. (Pubitemid 38950974)
38. Zhang KYJ (2006) Crystal structure of phosphodiesterase families and the potential for rational drug design, in Cyclic Nucleotide Phosphodiesterase in Health and Disease (Beavo J, Francis SH, and Houslay MD eds) pp 583-605, CRC Press, Boca Raton.
39. Zoraghi R, Corbin JD, and Francis SH (2006) Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity. J Biol Chem 281:5553-5558. (Pubitemid 43847651)
40. Zoraghi R, Francis SH, and Corbin JD (2007) Critical amino acids in phosphodiesterase- 5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. Biochemistry 46:13554-13563. (Pubitemid 350209951)